Explore the words cloud of the HIVACAR project. It provides you a very rough idea of what is the project "HIVACAR" about.
The following table provides information about the project.
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
|Coordinator Country||Spain [ES]|
|Total cost||6˙822˙299 €|
|EC max contribution||6˙685˙111 € (98%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-01-01 to 2021-12-31|
Take a look of project's partnership.
|1||CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER||ES (BARCELONA)||coordinator||2˙859˙183.00|
|2||FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA||ES (BARCELONA)||participant||714˙375.00|
|3||THE ROCKEFELLER UNIVERSITY NOT FOR PROFIT CORPORATION||US (NEW YORK)||participant||706˙250.00|
|4||AARHUS UNIVERSITET||DK (AARHUS C)||participant||496˙250.00|
|5||ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK||FR (PARIS)||participant||309˙275.00|
|6||ZABALA INNOVATION CONSULTING, S.A.||ES (MUTILVA ALTA NAVARRA)||participant||273˙125.00|
|7||AGENCIA ESTATAL CONSEJO SUPERIOR DEINVESTIGACIONES CIENTIFICAS||ES (MADRID)||participant||238˙063.00|
|8||ASSISTANCE PUBLIQUE HOPITAUX DE PARIS||FR (PARIS)||participant||216˙236.00|
|9||ETHERNA IMMUNOTHERAPIES||BE (NIEL)||participant||215˙000.00|
|10||VRIJE UNIVERSITEIT BRUSSEL||BE (BRUSSEL)||participant||198˙360.00|
|11||ASPHALION SL||ES (BARCELONA)||participant||175˙000.00|
|12||EUROPEAN AIDS TREATMENT GROUP EV||DE (DUSSELDORF)||participant||150˙000.00|
|13||UNIVERSIDAD COMPLUTENSE DE MADRID||ES (MADRID)||participant||128˙750.00|
|14||AELIX THERAPEUTICS SL||ES (BARCELONA)||participant||5˙242.00|
|15||Simon Fraser University||CA (BURNABY)||participant||0.00|
The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4 T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual costs related to HIV treatment and management and of the social public health as well as an improvement in the patients’ quality of life. HIVACAR project has been conceived under the framework of responsible research and innovation, so patients and other stakeholders will have a key role from the inception of the project until obtaining the results. Patients will be perfectly aware of how this therapy has been conceived and the real impact and change in their actual quality of life, as well as how the clinical trial has been designed and the consequences of participating in it. In addition, patients (and the general population) will tailor the project and its results dissemination and communication. This patient engagement will not be limited to the clinical trial but also to the rest of the activities of the project, so patients and the general society will be aware of how the research is developed and can include the patients’ point of view in the research activities. In addition, the socio-economic and psycho-social impact of the new treatment will be also analysed so overwhelming data on the benefits and impact of the new treatment will be obtained and shown to all the stakeholders.
|Intermediate report on dissemination activities||Documents, reports||2020-02-19 17:35:24|
|Targeted communication tools||Documents, reports||2020-02-19 17:35:24|
|Final Briefing Document sent to EMA to request Scientific Advice containing information on the quality, nonclinical and clinical development program||Documents, reports||2020-02-19 17:35:24|
|Data Management Plan||Documents, reports||2020-02-19 17:35:24|
|Communication plan||Other||2020-02-19 17:35:24|
|HIVACAR Phase I/IIa clinical trial protocol||Documents, reports||2020-02-19 17:35:24|
Take a look to the deliverables list in detail: detailed list of HIVACAR deliverables.
|year||authors and title||journal||last update|
Beatriz Perdiguero, Cristina SÃ¡nchez-Corzo, Carlos Oscar S. Sorzano, Lidia Saiz, Pilar Mediavilla, Mariano Esteban, Carmen Elena GÃ³mez
A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses
published pages: 160, ISSN: 1999-4915, DOI: 10.3390/v11020160
Beatriz Perdiguero; Suresh C. Raman; Cristina SÃ¡nchez-Corzo; Carlos Oscar S. Sorzano; JosÃ© RamÃ³n Valverde; Mariano Esteban; Carmen Elena GÃ³mez
Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B
published pages: 424, ISSN: 1999-4915, DOI: 10.3390/v10080424
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HIVACAR" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HIVACAR" are provided by the European Opendata Portal: CORDIS opendata.
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients with Bone MetastasisRead More
Collaboration for innovation: Establishment of a pan-nematode drug development platformRead More
Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in OsteoarthritisRead More